Table 3 Response to various therapies after the first disease progression.

From: Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients

Patient ID Figure ID Type Marker mutation Treatment Initiation of new treatment (1) Assay before new treatment (2) Assay after new treatment (2) Response evaluation (2) PM score of the first assay PM score of the second assay MART Objective response
5 2B type I L858R CDDP+PEM 454 −1 21 28 15057 65 0.004 NE
6 S3D type I exon 19 deletion local radiation (brain) 527 −20 68 n/a 9865 19738 2.000 radiation
6 S3D type I exon 19 deletion CBDCA+nabPTX 644 −49 15 42 19738 18724 0.949 PD
7 S3E type I exon 19 deletion CDDP+PEM 172 −1 57 57 2206 n.d. 0.000 PD
8 S3F type I exon 19 deletion CDDP+PEM 209 −5 43 93 n.d. 572 572 SD
9 3 type I exon 19 deletion local radiation (brain) 358 −8 17 n/a 4461 8619 1.932 radiation
9 3 type I exon 19 deletion CBDCA+PEM+BEV 378 −3 71 84 8619 261 0.030 PR
9 3 type I exon 19 deletion PEM 504 −14 28 56 n.d. 1254 1254 PD
9 3 type I exon 19 deletion S1+BEV 589 0 98 49 7171 3153 0.440 SD
9 3 type I exon 19 deletion gefitinib 729 0 41 56 464 639 1.377 PD
9 3 type I exon 19 deletion AZD9291 889 0 21 36 31119 157 0.005 PR
9 3 type I exon 19 deletion docetaxel 994 −84 42 21 157 33872 216 PD
9 3 type I exon 19 deletion AMR 1064 −28 35 21 33872 52361 1.546 PD
10 S3G type I L858R gefitinib+GEM 353 −28 7 10 n.d. 431 431 PD
10 S3G type I L858R gefitinib+PEM 381 −7 42 71 n.d. n.d. n/a NE
10 S3G type I L858R local radiation (illium) 531 −45 19 n/a 326 2484 7.620 radiation
11 2C type I T790M CBDCA+nabPTX 334 −1 28 133 1797 29 0.016 PR
11 2C type I T790M erlotinib 518 −30 45 47 n.d. n.d. n/a SD
12 2D type II exon 19 deletion erlotinib 336 −56 28 61 10176 24447 2.402 PD
14 2D type II exon 19 deletion local radiation (bone) 495 −18 4 n/a 13650 30448 2.231 radiation
14 2F type II exon 19 deletion CBDCA+PTX+BEV 510 −11 8 n/a 30448 1789 0.059 NE
15 S3H type II L861Q CDDP+PEM 363 −2 32 76 620 n.d. 0.002 PR
15 S3H type II L861Q PEM 489 −94 42 30 n.d. n.d. n/a SD
  1. (1) Days counted form initiation of EGFR-TKI. (2) Days counted form initiation of new treatment. n/a, not applicable; n.d., not detected.
  2. MART is calculated assgining 1 for"n.d." of single "n.d." cases. GEM, gemcitabine.